Clinical Variation in the Treatment Practices for Medication Nonadherence, Drug-Drug Interactions, and Recognition of Disease Progression in Patients with Chronic Cardiometabolic Diseases: A Cross-Sectional Patient Simulation Study among Primary Care Physicians

Czarlota Valdenor, Divya Ganesan, David Paculdo, Joshua Schrecker, Rebecca Heltsley, Christopher Westerfield, John W Peabody, Czarlota Valdenor, Divya Ganesan, David Paculdo, Joshua Schrecker, Rebecca Heltsley, Christopher Westerfield, John W Peabody

Abstract

Background: Medication nonadherence in patients with chronic diseases is common, costly, and often underdiagnosed. In the United States, approximately 40-50% of patients with cardiometabolic conditions are not adherent to long-term medications. Drug-drug interactions (DDI) are also underrecognized and may lead to medication nonadherence in this patient population. Treatment complexity associated with cardiometabolic conditions contributes to increased risk for adverse drug events and DDIs.

Methods: We recruited a nationally representative sample of 246 board-certified family and internal medicine physicians to evaluate how they assessed, identified, and treated medication nonadherence, DDIs, and worsening disease. Participating physicians were asked to care for three online simulated patients, each with at least one chronic cardiometabolic disease, including atrial fibrillation, heart failure, diabetes mellitus, or hypertension, and who were taking prescription medications for their disease. Physicians' scores were based on evidence-based care recommendation criteria, including overall care quality and treatment for medication nonadherence and DDIs.

Results: Overall, quality-of-care scores across all cases ranged from 13% to 87% with an average of 50.8% ± 12.1%. The average overall diagnostic plus treatment score was 21.9% ± 13.6%. Participants identified nonadherence in just 3.6% of cases, DDIs in 8.9% of cases, and disease progression in 30.3% of cases.

Conclusions: Based on these study results, primary care physicians were unable to adequately diagnose and treat patients with chronic cardiometabolic diseases who either suffered from medication nonadherence, DDIs, or progression of the disease. Improved standardization and technique in identifying these diagnoses is needed in primary care. Trial Registration. This trial is registered with clinicaltrials.gov, NCT05192590.

Conflict of interest statement

JS, RH, and CW are employees of Aegis Sciences Corporation. The other authors declare that they have no conflicts of interest.

Copyright © 2022 Czarlota Valdenor et al.

Figures

Figure 1
Figure 1
Overall CPV scores.

References

    1. Berkowitz S. A., Hulberg A. C., Standish S., Reznor G., Atlas S. J. Addressing unmet basic resource needs as part of chronic cardiometabolic disease management. JAMA Internal Medicine . 2017;177(2):244–252. doi: 10.1001/jamainternmed.2016.7691.
    1. McClellan M., Brown N., Califf R. M., Warner J. J. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American heart association. Circulation . 2019;139(9):e44–e54. doi: 10.1161/CIR.0000000000000652.
    1. Joynt Maddox K. E., Bleser W. K., Das S. R., et al. Value in healthcare initiative. Circulation: Cardiovascular Quality and Outcomes . 2020;13(7) doi: 10.1161/CIRCOUTCOMES.120.006612.e006612
    1. Geller J. C. Time to act - guideline-defined treatment goals for cardiovascular risk factors are not achieved in primary care. European Cardiology Review . 2008;4(2):24–26. doi: 10.15420/ecr.2008.4.2.24.
    1. Gholami K., Ziaie S., Shalviri G. Pharmacy Practice . Vol. 6. 5: 2008. Adverse drug reactions induced by cardiovascular drugs in outpatients; pp. 51–5.
    1. Kleinsinger F. The unmet challenge of medication nonadherence. The Permanente Journal . 2018;22:18–033. doi: 10.7812/TPP/18-033.
    1. Xu H.-Y., Yu Y.-J., Zhang Q.-H., Hu H.-Y., Li M. Tailored interventions to improve medication adherence for cardiovascular diseases. Frontiers in Pharmacology . 2020;11 doi: 10.3389/fphar.2020.510339.510339
    1. Marcum Z. A., Sevick M. A., Handler S. M. Medication nonadherence. JAMA . 2013;309(20):2105–2106. doi: 10.1001/jama.2013.4638.
    1. Brown M. T., Bussell J. K. Medication adherence: WHO cares? Mayo Clinic Proceedings . 2011;86(4):304–314. doi: 10.4065/mcp.2010.0575.
    1. Basu S., Garg S., Sharma N., Singh M. M. Improving the assessment of medication adherence: challenges and considerations with a focus on low-resource settings. Tzu Chi Medical Journal . 2019;31(2):73–80. doi: 10.4103/tcmj.tcmj_177_18.
    1. Peabody J., Acelajado M. C., Robert T., et al. Drug-drug interaction assessment and identification in the primary care setting. Journal of Clinical Medicine Research . 2018;10(11):806–814. doi: 10.14740/jocmr3557w.
    1. Us Food and Drug Administration. Drug Interactions: What You Should Know. 2013. .
    1. Tannenbaum C., Sheehan N. L. Understanding and preventing drug-drug and drug-gene interactions. Expert Review of Clinical Pharmacology . 2014;7(4):533–544. doi: 10.1586/17512433.2014.910111.
    1. Kovačević M., Vezmar Kovačević S., Miljković B., Radovanović S., Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. International Journal of Clinical Practice . 2017;71(10) doi: 10.1111/ijcp.13005.e13005
    1. Peabody J., Tran M., Paculdo D., Schrecker J., Valdenor C., Jeter E. Clinical utility of definitive drug-drug interaction testing in primary care. Journal of Clinical Medicine . 2018;7(11):p. 384. doi: 10.3390/jcm7110384.
    1. Peabody J., Schrecker J., Heltsley R., et al. Randomized trial to improve primary care patient management and patient outcomes using a drug-drug interaction test: confirmation of the DECART simulated patient clinical utility trial results. Diagnostics . 2021;11(7):p. 1266. doi: 10.3390/diagnostics11071266.
    1. Holford N. Treatment response and disease progression. Translational and Clinical Pharmacology . 2019;27(4):123–126. doi: 10.12793/tcp.2019.27.4.123.
    1. Zhu Z., Heng B. H., Teow K. L. Lifetime trajectory simulation of chronic disease progression and comorbidity development. Journal of Biomedical Informatics . 2018;88:29–36. doi: 10.1016/j.jbi.2018.11.002.
    1. Brown M., Sinsky C. A. Medication adherence: we didn’t ask and they didn’t tell. Family Practice Management . 2013;20(2):25–30.
    1. Peabody J. W., Luck J., Glassman P., Dresselhaus T. R., Lee M. Comparison of vignettes, standardized patients, and chart abstraction. JAMA . 2000;283(13):1715–1722. doi: 10.1001/jama.283.13.1715.
    1. Peabody J., Luck J., Glassman P., et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Annals of Internal Medicine . 2004;141(10):771–780. doi: 10.7326/0003-4819-141-10-200411160-00008.
    1. Burgon T. B., Cox-Chapman J., Czarnecki C., et al. Engaging primary care providers to reduce unwanted clinical variation and support ACO cost and quality goals: a unique provider-payer collaboration. Population Health Management . 2019;22(4):321–329. doi: 10.1089/pop.2018.0111.
    1. Walsh C. A., Cahir C., Tecklenborg S., Byrne C., Culbertson M. A., Bennett K. E. The association between medication non‐adherence and adverse health outcomes in ageing populations: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology . 2019;85(11):2464–2478. doi: 10.1111/bcp.14075.
    1. da Silva B. A., Krishnamurthy M. The alarming reality of medication error: a patient case and review of Pennsylvania and National data. Journal of Community Hospital Internal Medicine Perspectives . 2016;6(4) doi: 10.3402/jchimp.v6.31758.31758
    1. Lane D., Patel P., Khunti K., Gupta P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Preference and Adherence . 2019;13:537–547. doi: 10.2147/PPA.S162215.
    1. Willis J., Antono B., Bazemore A., et al. The State of Primary Care in the United States: A Chartbook of Facts and Statistics . Washington, DC, USA: Robert Graham Center; 2020.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner